Józwiak Michalina, Bauer Marta, Kamysz Wojciech, Kleczkowska Patrycja
Maria Sklodowska-Curie Medical Academy in Warsaw, 03-411 Warsaw, Poland.
Department of Analytical Chemistry, Faculty of Pharmacy, Medical University of Gdansk, 80-416 Gdansk, Poland.
Pharmaceuticals (Basel). 2025 Jan 30;18(2):185. doi: 10.3390/ph18020185.
BPC 157, known as the "Body Protection Compound", is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects in various preclinical models mimicking medical conditions, such as tissue injury, inflammatory bowel disease, or even CNS disorders. Unlike many other drugs, BPC 157 has a desirable safety profile, since only a few side effects have been reported following its administration. Nevertheless, this compound was temporarily banned by the World Anti-Doping Agency (WADA) in 2022 (it is not currently listed as banned by the WADA). However, it has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans. In this review, we summarize information on the biological activities of BPC 157, with particular reference to its mechanism of action and probable toxicity. This generated the attention of experts, as BPC 157 has been offered for sale on many websites. We also present recent interest in BPC 157 as reflected in a number of patent applications and granted patents.
BPC 157,即“身体保护化合物”,是一种从人胃液中分离出的十五肽,在模拟医学病症(如组织损伤、炎症性肠病甚至中枢神经系统疾病)的各种临床前模型中显示出其多效性有益作用。与许多其他药物不同,BPC 157具有良好的安全性,因为给药后仅报告了少数副作用。尽管如此,该化合物在2022年被世界反兴奋剂机构(WADA)暂时禁止(目前未被WADA列为禁用药物)。然而,由于缺乏足够全面的临床研究证实其对人类的健康益处,它尚未获得美国食品药品监督管理局(FDA)和其他全球监管机构在标准医学中的使用批准。在本综述中,我们总结了关于BPC 157生物活性的信息,特别提及了其作用机制和可能的毒性。这引起了专家们的关注,因为BPC 157已在许多网站上出售。我们还介绍了近期在一些专利申请和已授予专利中所反映出的对BPC 157的兴趣。